Vaccines

4 June 2024

TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)

1 June 2024

Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)

30 May 2024

BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem

30 May 2024

VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients

29 May 2024

CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK

29 May 2024

ILiAD Biotechnologies Reports Positive Topline Interim Results from Phase 2b School-Age Trial of BPZE1 Pertussis Vaccine

23 May 2024

Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines

21 May 2024

YGION Biomedical announces €15 Million Series A Financing to develop Individualized Cancer Immunotherapies

21 May 2024

Anokion Announces New Clinical Data from the Phase 1b/2 ACeD-it Trial Supporting KAN-101 as a Potential Disease-Modifying Treatment for Celiac Disease

21 May 2024

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine

17 May 2024

Inimmune announces successful phase 1 clinical results for disease modifying allergy treatment, INI-2004

14 May 2024

AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease

12 May 2024

Replicate Bioscience Presents Positive Data from Phase 1 Trial and Preclinical Data with Novel Self-Replicating RNA at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

10 May 2024

PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer

10 May 2024

Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines

10 May 2024

WestGene’s mRNA Therapeutic Cancer Vaccine Receives FDA Approval

30 April 2024

Gritstone bio Highlights the Durability and Potential Broad Utility of its Self-amplifying mRNA (samRNA) COVID-19 Vaccine at ESCMID Global 2024

30 April 2024

Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers

29 April 2024

Bavarian Nordic Initiates Rolling Submission of Biologics License Application with FDA for its Chikungunya Vaccine Candidate

29 April 2024

Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases

29 April 2024

Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults

25 April 2024

Innorna’s broad-spectrum SARS-CoV-2 mRNA vaccine receives Phase II clinical trial approval from FDA

25 April 2024

HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers

24 April 2024

CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK

19 April 2024

Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections

18 April 2024

Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01

16 April 2024

Naobios and Sumagen sign exclusive partnership to develop HIV vaccine

11 April 2024

Stamford Pharmaceuticals Inc Announces the First Patient to Be Treated with SP-002 in Combination with Erivedge® in a Phase 2 Study in Locally Advanced BCC Subjects

9 April 2024

YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine

9 April 2024

Diakonos Oncology’s Unique Dendritic Cell Vaccine (DOC1021) Improves Survival Compared to Standard of Care in Phase 1 Trial for Glioblastoma

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

Report Package: “Drug the Undruggable” Technologies

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

5T4-Targeted Immunotherapy Candidates Pipeline Review

PD-1 Agonists Pipeline Review

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

Her3-Targeted Immunotherapy Pipeline Review

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

Claudin 18.2-Targeted Immunotherapeutics – a Competitor Analysis

Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review